Hepatitis B Virus (HBV) Therapeutics - Current and Future Players


Posted December 7, 2016 by Fiona-QYR

The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing HBV Market.

 
MRRS adds "Hepatitis B Virus (HBV) Therapeutics - Current and Future Players" latest studies, published in November 2016. It is a professional and in-depth study.

Table of Contents

1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Introduction 5
2.1 Catalyst 5
2.2 Related Reports 6
2.3 Upcoming Related Reports 7
3 Market Outlook 8
3.1 Global Markets 8
3.1.1 Forecast 8
3.1.2 Drivers and Barriers - Global Issues 14
4 Current and Future Players 17
4.1 Overview 17
4.2 Trends in Corporate Strategy 20
4.3 Company Profiles 23
4.3.1 Gilead 23
4.3.2 Bristol-Myers Squibb 25
4.3.3 Roche 27
4.3.4 Merck 28
4.3.5 GSK 30
4.3.6 Novartis 31
4.3.7 Arrowhead Research 32
4.3.8 GlobeImmune 33
5 Appendix 34
5.1 Bibliography 34
5.2 Abbreviations 56
5.3 Methodology 62
5.4 Forecasting Methodology 62
5.4.1 Total Prevalent Cases of Chronic Hepatitis B 62
5.4.2 Diagnosed Chronic Hepatitis B Patients 63
5.4.3 Percent Drug-Treated Chronic Hepatitis B Patients 63
5.4.4 Drugs Included in Each Therapeutic Class 64
5.4.5 Launch and Patent Expiry Dates 64
5.4.6 General Pricing Assumptions 65
5.4.7 Individual Drug Assumptions 67
5.4.8 Generic Erosion 74
5.4.9 Pricing of Pipeline Agents 75
5.5 Primary Research - KOLs Interviewed for this Report 76
5.6 Primary Research - Prescriber Survey 80
5.7 About the Authors 81
5.7.1 Analyst 81
...

Browse Complete Report with TOC @
[URL]http://www.marketresearchreportstore.com/shop/hepatitis-b-virus-hbv-therapeutics-current-and-future-players[/URL]

List of Tables and Figures

1.1 List of Tables
Table 1: Global Sales Forecasts ($m) for Chronic Hepatitis B Therapeutics, 2014-2024 11
Table 2: Chronic Hepatitis B Therapeutics Market - Drivers and Barriers, 2014-2024 14
Table 3: Key Companies in the Chronic Hepatitis B Therapeutics Market, 8MM, 2015 19
Table 4: Gilead’s Chronic Hepatitis B Portfolio Assessment, 2015 25
Table 5: BMS’s Chronic Hepatitis B Portfolio Assessment, 2015 26
...

Any questions, please feel free to contact us:

Tel: +00-1-626-3463946 - U.S

Email: [email protected]

[URL]http://www.marketresearchreportstore.com/[/URL]
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Market Research Report Store
Country China
Categories Business
Last Updated December 7, 2016